Vaxcyte Up on Pneumococcal Conjugate Vaccine Data

Vaxcyte, Inc. (PCVX Quick QuotePCVX - Free Report) , a clinical-stage vaccine innovation company, saw its shares rise 16% after it released positive data from the phase II study of its 24-Valent pneumococcal conjugate vaccine (PCV) candidate, VAX-24, in adults aged 65 and older.